Danel Mayer CEO EndoStream Medical
Kaneka Corporation, a Japanese company, acquired a 96.8% stake in Israeli startup EndoStream Medical Ltd, an Israeli startup developing technologies in the field of cerebrovascular diseases. This acquisition aims to combine Kaneka’s manufacturing capabilities with EndoStream’s technology to jointly develop new medical devices, primarily for cerebrovascular treatment. While the purchase price was not disclosed, Calcalist estimated the value of EndoStream to be $100 million.
Cerebrovascular disease is a group of conditions that affect the blood vessels and blood supply to the brain. These conditions can cause a variety of problems, including stroke, which is a leading cause of death and disability in the United States.
There are many different types of cerebrovascular disease, but they all have one thing in common: they affect the flow of blood to the brain. This can happen when blood vessels become narrowed or blocked, or when they rupture and bleed. When brain cells don’t get enough blood, they can die, leading to a variety of symptoms depending on the location and severity of the damage.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Kaneka is developing its business in a wide range of fields, which include devices for the treatment of cardiac, peripheral vascular, and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases. In the growing field of cerebrovascular diseases, among others, we provide “i-ED COIL™”, an embolization coil that prevents damage to cerebral aneurysms that cause subarachnoid hemorrhage. Thus, we are expanding our product portfolio for further growth. The Health Care Solution Unit, which includes these medical businesses, aims to achieve sales of 300 billion Yen ($1.88 billion) by 2030.
EndoStream Medical Ltd., founded in 2015 by CEO Danel Mayer and CTO Alon May, and headquartered in Or Akiva, Israel, specializes in developing innovative medical devices for the treatment of cerebral aneurysms. Their flagship product, the Nautilus™ Intrasaccular System, is a minimally invasive device designed to treat wide-necked aneurysms by maximizing neck coverage and enhancing coil stability, promoting intrasaccular thrombosis and enabling progressive occlusion.
In November 2024, the Nautilus™ device received regulatory approval in Europe, with plans for approval and launch in the United States in the spring of 2026 and in Japan one year later.
EndoStream’s leadership includes Founder and CEO Danel Mayer, who previously founded Rapid Medical, and Founder and CTO Alon May, who has extensive experience leading complex engineering projects in medical device startups.
EndoStream Medical’s mission is to develop safe and effective solutions that significantly improve clinical outcomes for patients suffering from brain aneurysms.
